{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:29:42Z","timestamp":1791073782959,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"7340","license":[{"start":{"date-parts":[[2002,3,30]],"date-time":"2002-03-30T00:00:00Z","timestamp":1017446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2001,12,19]]},"published-print":{"date-parts":[[2002,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design:<\/jats:bold>\n                    Randomised, double blind, parallel group study of 18 weeks' duration.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting:<\/jats:bold>\n                    13 general practices and a teaching hospital in the Nottingham area.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Participants:<\/jats:bold>\n                    174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions:<\/jats:bold>\n                    0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measures:<\/jats:bold>\n                    Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval \u22122.0 to 4.0, P=0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity and quality of life compared with baseline.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text id=\"FB1\" position=\"float\">\n                      <jats:sec>\n                        <jats:title>What is already known on this topic<\/jats:title>\n                        <jats:p>Topical corticosteroids have been used to control atopic eczema for 40 years<\/jats:p>\n                        <jats:p>No studies have compared short bursts of a potent preparation with prolonged use of a weak preparation for controlling mild or moderate disease<\/jats:p>\n                      <\/jats:sec>\n                      <jats:sec>\n                        <jats:title>What this study adds<\/jats:title>\n                        <jats:p>A short burst of a potent topical steroid is as effective and safe as prolonged use of a weak preparation for mild or moderate atopic eczema<\/jats:p>\n                        <jats:p>The type of preparation is immaterial provided that the dosage is adequate<\/jats:p>\n                      <\/jats:sec>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1136\/bmj.324.7340.768","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:30:44Z","timestamp":1027751444000},"page":"768.1","source":"Crossref","is-referenced-by-count":121,"title":["Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema"],"prefix":"10.1136","volume":"324","author":[{"given":"K S","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Li Wan","family":"Po","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H C","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2002,3,30]]},"reference":[{"key":"2025122121163220000_324.7340.768.1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02316.x"},{"key":"2025122121163220000_324.7340.768.2","doi-asserted-by":"crossref","unstructured":"Williams HC Wuthrich B .The natural history of atopic dermatitis. In: Williams HC , ed. Atopic dermatitis. Cambridge:Cambridge University Press,2000,41\u201359.","DOI":"10.1017\/CBO9780511545771.005"},{"key":"2025122121163220000_324.7340.768.3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/bmj.310.6983.843","article-title":"Treatment of atopic eczema.","volume":"310","author":"McHenry","year":"1995","journal-title":"BMJ"},{"key":"2025122121163220000_324.7340.768.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03473.x"},{"key":"2025122121163220000_324.7340.768.5","first-page":"10","article-title":"Compliance problems in paediatric atopic eczema.","volume":"37","author":"Fisher","year":"1996","journal-title":"Aust J Dermatol"},{"issue":"37","key":"2025122121163220000_324.7340.768.6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3310\/hta4370","article-title":"Systematic review of treatments for atopic eczema.","volume":"4","author":"Hoare","year":"2000","journal-title":"Health Technol Assess"},{"key":"2025122121163220000_324.7340.768.7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1525-1470.1996.tb01211.x","article-title":"A reappraisal of topical steroid potency.","volume":"13","author":"Hepburn","year":"1996","journal-title":"Pediatr Dermatol"},{"key":"2025122121163220000_324.7340.768.8","doi-asserted-by":"crossref","unstructured":"Hornstein O .Guidelines for topical treatment of atopic eczema. In: Ruzicka T Ring J Pryzbilla B , eds. Handbook of atopic eczema. Heidelberg:Springer-Verlag,1991:350.","DOI":"10.1007\/978-3-662-02671-7_37"},{"key":"2025122121163220000_324.7340.768.9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1525-1470.1996.tb00737.x","article-title":"A 3-day rate of efficacy of a moderate potency topical steroid in the treatment of atopic dermatitis in infancy and childhood.","volume":"13","author":"Schachner","year":"1996","journal-title":"Pediatr Dermatol"},{"key":"2025122121163220000_324.7340.768.10","unstructured":"British Medical Association, Royal Pharmaceutical Society of Great Britain .British national formulary. London:BMA, RPS,2000:508\u2013520. (No 40.)"},{"key":"2025122121163220000_324.7340.768.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08530.x"},{"key":"2025122121163220000_324.7340.768.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03300.x"},{"key":"2025122121163220000_324.7340.768.13","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.6.763"},{"key":"2025122121163220000_324.7340.768.14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.1996.tb00706.x","article-title":"Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis.","volume":"135","author":"Berth-Jones","year":"1996","journal-title":"Br J Dermatol"},{"key":"2025122121163220000_324.7340.768.15","first-page":"19","article-title":"How much disability does atopic eczema cause compared with other health problems?","volume":"137","author":"Emerson","year":"1997","journal-title":"Br J Dermatol"},{"key":"2025122121163220000_324.7340.768.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02034.x"},{"key":"2025122121163220000_324.7340.768.17","unstructured":"Personal Social Services Research Unit . Netton A Dennett J , eds. Unit costs of health and social care. Canterbury:PSSRU,2000:sections 6.1, 8.7."},{"key":"2025122121163220000_324.7340.768.18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04430.x"},{"key":"2025122121163220000_324.7340.768.19","unstructured":"Serup JKJ Fullerton A .High-frequency ultrasound examination of skin: introduction and guide. In: Serup JJ Jemec GBE , eds. Handbook of non-invasive methods and the skin. London:CRC Press,1995."},{"key":"2025122121163220000_324.7340.768.20","unstructured":"Van Onselen J .Dermatology care: the next role for primary care nurses. Community Nurse 1998; Sept: 28\u201330."},{"key":"2025122121163220000_324.7340.768.21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1046\/j.1365-2133.1999.02893.x","article-title":"The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate.","volume":"140","author":"Van der Meer","year":"1999","journal-title":"Br J Dermatol"},{"key":"2025122121163220000_324.7340.768.22","unstructured":"Sillevis S Spuls P Van Leent E Vries H Mulder P Glazenburg E .Randomized double blind comparison of continuous versus pulse topical treatment with clobetasone butyrate in 40 children with atopic dermatitis. In: International symposium on atopic dermatitis. Portland, OR:National Eczema Association for Science and Education,2001."},{"key":"2025122121163220000_324.7340.768.23","first-page":"533","article-title":"Intermittent dosing with topical fluticasone propionate delays the time to relapse in adults and children with chronic atopic dermatitis\u2014two randomised controlled studies.","volume":"117","author":"Glazenburg","year":"2001","journal-title":"J Invest Dermatol"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.324.7340.768","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.324.7340.768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:16:39Z","timestamp":1766380599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.324.7340.768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,30]]},"references-count":23,"journal-issue":{"issue":"7340","published-online":{"date-parts":[[2002,3,30]]},"published-print":{"date-parts":[[2002,3,30]]}},"alternative-id":["10.1136\/bmj.324.7340.768"],"URL":"https:\/\/doi.org\/10.1136\/bmj.324.7340.768","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,30]]}}}